1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors.
Saved in:
| Title: | 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. |
|---|---|
| Authors: | Chauhan, A.1 (AUTHOR), Reis, I.2 (AUTHOR), Jani, C.T.3 (AUTHOR), Modak, R.1 (AUTHOR), Bilbao, D.4 (AUTHOR), Merchan, J.R.5 (AUTHOR), Lopes, G.6 (AUTHOR), Hosein, P.7 (AUTHOR), Hallenbeck, P.8 (AUTHOR), Trinh, H.9 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1019-S1019. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
